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Background: Death receptors (DRs) play an important role in renal pathology. We have shown that DR3 is inducibly
expressed on renal tubular epithelial cells in the setting of inflammatory injuries. In this study we investigate the
expression of DR3 in renal endothelial cells and their response to TL1A, the only known ligand of DR3.
Methods: We did RT-PCR, flow cytometry and subcellular immunoblotting to examine the expression and function of
DR3 in cells in vitro. We did organ culture of human and mouse tissue to examine expression and signal of DR3 in vivo.
Results: DR3 is expressed in some interstitial vascular endothelial cells (EC) in human kidney in situ; these EC also
respond to its ligand TL1A by activating NF-κB. Very low levels of DR3 can be detected on the cell surface of cultured
human umbilical vein (HUV) EC, which do not respond to TL1A. HUVEC transfected to overexpress DR3 become
responsive to TL1A, assessed by IκBα degradation and E-selectin induction, indicating that the signaling components
needed for DR3 responsiveness are expressed. TL1A induces NF-κB activation in EC in renal and cardiac tissue from wild
type but not DR3 knock-out mice.
Conclusion: TL1A and DR3 activate NF-κB in vascular endothelial cells, and can be an important regulator of renal
interstitial vascular injury.
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Death receptors (DRs) of the tumor necrosis factor
receptor (TNFR) superfamily include TNFR1, Fas,
DR3, DR4, DR5 and DR6. The members of DR family
each contain an intracellular death domain (DD) that
binds to adaptor proteins which also contain DDs
and initiate apoptotic cell death [1]. The DD of DR3
shares the highest homology with that of TNFR1 (47%)
[2], and, like TNFR1, interacts with the DD-containing
silencer of death domain (SODD) in the absence of ligand,
whereas the other four DRs do not [3,4]. Furthermore,
upon ligand binding, only DR3 and TNFR1 recruit the
adaptor TNFR-associated death domain (TRADD) protein
and assemble a TRADD-dependent signalling complex
that rapidly triggers NF-κB and c-Jun N-terminal kinase
(JNK) activation; after a delay of several hours the TRADD
signalosome recruits Fas-associated DD (FADD) protein
that may trigger apoptosis [5]. However, in contrast to* Correspondence: jw270uk@hotmail.co.uk
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unless otherwise stated.TNFR1, which is expressed on a wide range of cell types,
DR3 expression is more restricted [6] and most commonly
associated with T cells. Two different species of messenger
RNA (mRNA) encoding a transmembrane form of DR3,
DR3 and DR3β have been isolated from of a panel of
human lymphoid cell lines. Eleven splice variants of
DR3 mRNA have been identified in peripheral blood
lymphocytes, and upon activation by phytohaemagglutinin
(PHA), the transcript level is up-regulated [7,8]. Much less
is known about regulation and expression of DR3 protein
or about its isoforms in non-lymphoid cells. We have
previously reported that DR3 mRNA and protein are
induced on non-lymphoid cells of human kidney allografts
undergoing acute cellular rejection [9]. Specifically, we
observed that DR3 is predominatly up-regulated in
tubular epithelial cells but we also observed expression of
DR3 in some peritubular endothelial cells (EC), albeit not
in glomerular EC.
The only known ligand for DR3 is TNF-like molecule 1A
(TL1A), a TNF superfamily member, and mRNA encoding
this protein is most abundantly expressed in kidney tissue;td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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growth inhibitor, VEGI) [10]. Both TL1A mRNA and
protein are also up-regulated by the same pathological
processes that control DR3 expression in renal epithelial
cells [11]. In situ hybridization suggested that EC are a
major source of TL1A in the human kidney. The
TL1A-DR3 system may thus play an important role
in the vasculature in renal injury and inflammation.
Human umbilical vein (HUV) ECs are a major source
of TL1A synthesis among cultured cell types, but it is
not known whether EC respond to this ligand. We
have investigated fully the expression and function of
DR3 in human EC in this study.
Methods
Materials
Mouse monoclonal anti-human DR3 was purchased
from Chemicon (Southampton, U.K). Rabbit anti-human
IκBα and goat anti-human DR3 antibodies were from
Santa Cruz (Wiltshire, U.K). Horse anti-goat and goat
anti-rabbit horseradish peroxidase (HRP)-conjugated
antibodies and Vectashield Mounting Media were from
Vector Laboratories Ltd (Peterborough, U.K). Rabbit
anti-human NF-κB p65 was purchased from Serotec
(Oxford, U.K). Rabbit anti-human phospho-NF-κB p65
was from New England Biolab (Hertfordshire, U.K).
Proteinase inhibitor cocktail was purchased from Roche
Diagnostics Ltd (East Sussex, U.K). Human recombinant
TL1A, human recombinant TNF-α and goat anti-human
DR3 antibody were purchased from R&D Systems Europe
(Abingdon, U.K). Chicken anti-rabbit Alexafluor488,
goat anti-mouse Alexafluor568, Lipofectin reagent and
Opti-MEM media were from Invitrogen Ltd (Paisley, U.K).
The ECL system was from Amersham Pharmacia Biotech
UK Ltd (Bukinghamshire, U.K).
Unless otherwise indicated, all reagents were from
Sigma-Aldrich Company Ltd (Dorset, U.K).
All experiments using human tissue were performed
with written, informed consent of patients and the
approval of Local Ethical Committee which is East of
England - Cambridge Central Research Ethics Committee
and Addenbrooke’s Hospital Tissue Bank. Renal tissues
was obtained from the uninvolved pole of kidney excised
less than half an hour before because of renal tumours or
from time zero biopsy of kidney transplant.
Kidney organ culture
Duplicate 1 mm3 fragments of kidney tissue were placed in
flat-bottomed 96-well tissue culture plates and immediately
immersed in medium M199 containing 10% heat inacti-
vated bovine fetal calf serum (FCS) and 2 mM L-glutamine.
Tissue was incubated for 3 hours at 37°C with either culture
media alone or with 5 ng/ml TNF-α (TNF) or 0.2 μg/ml
TL1A. Half of the harvested tissue was cryoprotected in30% sucrose in 0.1 M phosphate buffer and snap frozen in
isopentane-cooled liquid nitrogen and half was immersed in
4% paraformaldehyde in 0.1 M PIPES buffer pH 7.6 for
1.5 hours at 4°C and processed for paraffin-wax embedding.
Immunolabelling of tissue
8 μm-thick cryosections of kidney tissue processed as
above were permeabilized in cold methanol at −20°C for
5 minutes, washed in Milli-Q water and rinsed in 0.1 M
Tris–HCl buffer pH 7.5 containing 0.01% TWEEN-20
(TBS) prior to incubation with blocking buffer (10% FCS
in TBS) for 10 minutes. Sections were immunolabelled
as previously described [11] Sections were then washed
and mounted in Vectashield Mounting Media and imaged
with Leica SPE confocal laser scanning microscope (Leica
Microsystem Ltd, Milton Keynes, U.K).
Cell culture
Human umbilical vein EC (HUVEC) were from Lonza
(Cambrdige, UK) and serially cultured as previously
described [12]. Human dermal microvascular cells
(HDMEC) and human pulmonary artery endothelial cells
(HPAEC) obtained from Life Technology (Paisley, UK)
were cultured following the supplier’s instruction. Cells were
used at passages 1–3. Such cultures are free of detectable
leukocytes by immunostaining for CD45. TF-1 human
erythroleukemia cells obtained from American Tissue
Culture Centre (LGC Promochem, Middlesex, U.K) were
cultured in media as supplier required.
RT-PCR
Total RNA was isolated from cells using RNeazy Mini
Kit (QIAGEN Ltd, West Sussex, U.K). 1 μg total RNA was
amplified with DR3 forward (5′-GTAGCCCCAGGTGT
GACTGT-3′) and DR3 reverse (5′-GCTTGAGCATCTCG
TACTGC-3′) using Access RT-PCR system (Promega,
Southampton, U.K); the PCR product was visualized by 1%
low melting temperature agarose gel in Tris-Acetate-EDTA
buffer before purified with Wizard PCR Preps (Promega, U.
K). The purified DNA was sequenced in Lark Technologies
Inc (Essex, U.K).
Measurement of cell surface receptor expression by flow
cytometry
HUVEC were seeded into 6-well tissue culture plate
(1.5 × 105 cells per well), and 24 hours later the confluent
cells were treated with IFN-γ 500 U/ml, or TNF-α 500U/ml
or the combination of both for 24 and 48 hours. Cells
were harvested using a non-enzymatic cell suspension
solution. TF-1 cells (106/ml) were centrifuged down. Cells
were immunolablled and Fixed before analyzed by flow
cytometry using FACSCalibur machine (BD Biosciences,
Oxford, U.K) as previously described [12]. Data were
analyzed using WinMDI 2.8 software.
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HUVEC were washed once with PBS and scraped into
homogenization buffer (10 mM Tris HCl, pH 7.4; 3%
sucrose w/v; proteinase inhibitor cocktail, 1 mM PMSF).
TF-1 cells were pelleted by centrifugation, washed once
with PBS and resuspended in homogenization buffer. All
steps were performed at 4°C as previously described [12].
The protein concentration of each fraction was determined
by BCA protein assay kit (Pierce, Chester, U.K). Samples
were stored at −80°C before analysis by immunoblotting.
Generation of DR3-flag construct and transfection
The open reading frame of the human DR3 gene was iso-
lated by reverse transcription using the forward primer 5′-
TAGCGAATTCAATGGAGCAGCGGCCGCGGG-3′ and
the reverse primer 5′-GCGCTCTAGAAACCGTACTTAG
GGCTTCTGC-3′. The amplified product was ligated
in-frame into the pFlag-CMV1 vector (Sigma-Aldrich
Company Ltd, Dorset, U.K). DR3-Flag constructs were
introduced into passage 1 HUVEC by transient transfection.
In brief, HUVEC grown to 70% confluence on 100 mmFigure 1 Response of vascular endothelial cells in human kidney in o
incubated with either culture media alone or with TL1A (0.2 μg/ml) or TNF
show EC staining for NF-κBp65 (green) in both the glomerular (inset) and i
staining for DR3 (red). (D-F) Cultures treated with TL1A show co-staining for N
show no signal for NF-κBp65 on glomerular EC. (G-I) In contrast, TNF-treated
(inset) and peritubular blood vessels. DR3 (red) is present only in EC of peritubdiameter plastic culture plates or 6-well plates were
transfected approximately 2 hours with DR3-Flag using
Lipofectin reagent in Opti-MEM media following manu-
facture’s instruction. Cells were cultured for another 48
hours. Cells transfected with empty vector or DR3-Flag
were treated with TNF 5 ng/ml or TL1A 0.2 μg/ml for 2 or
4 hours. Cells were then collected for analyzing by flow
cytometry as described above.
Immunoblotting
HUVEC transfected with control vector or DR3-Flag
were stimulated with 0, 0.02, 0.2, 2 μg/ml TL1A or 0, 1,
5, 10 ng/ml TNF for 30 minutes and then washed once
with ice cold PBS before lysed in lysis buffer (62.5 mM
Tris, 2% SDS, 10% glycerol, 10 mM sodium orthovanadate,
10 mM sodium fluoride, proteinase inhibitor cocktail).
Samples (20 μg for IκBα, 50 μg for subcellular fraction)
were immunoblotted and detected as previously described
[12]. Serial dilution of samples for immunoblotting
confirmed that the density of bands was within the linear
range of detection.rgan culture to TL1A. Confocal images of kidney organ culture
(5 ng/ml) for 3 hours at 37°C. (A-C) cultures incubated in media alone
n peritubular vassels. Some peritubular vessels EC showed positive
F-κBp65 (green) and DR3 (red) in EC of some blood vessel (arrows). Inset;
cultures show a strong signal for NF-κB p65 (green) in EC of glomerular
ular blood vessels negative for NF-κB p65. (Original Mags; x40).
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Protocols involving animal were approved by the U.K
home office and the Cambridge University Local Ethical
Committee. C57Bl/6 DR3−/− mice were crossed once into
a CD1 background, and the F1 heterozygote progeny were
crossed to yield DR3+/+ wild type (WT) and DR3−/− knock-
out (KO) littermates. Animals were killed and the kidneys
and hearts were harvested and processed as described
in the previous section.
Statistical analysis
The significance of difference between experimental values
was assessed by means of the paired Student’s t test.
Results
Activation of NF-κB by TL1A in kidney organ culture
We have previously reported that EC in the interstitium of
normal human kidney are positive for DR3 but glomerular
EC are negative for DR3 [9]. To investigate whether the
DR3 positive EC in renal interstitium respond to TL1A,
we examined their ability to activate NF-κB in a kidney
organ culture model, using TNF treatment as a control.Figure 2 Expression of DR3 in TF-1 and HUVEC. (A) RT-PCR showed HU
TF-1 cells. (B) Flow cytometry using a monoclonal antibody to DR3 showed
expression on HUVEC. (C) Immunoblotting with antibody to DR3 C-terminus
fraction, containing mainly cell membrane protein. A DR3 band in TF-1 cells w
also showed a 35kDa band in the soluble subcellular fraction. (D) TL1A induc
(5 ng/ml) and TL1A (0.2 ug/ml) both induced IκBα degradation, phosphor-NF
of TF-1 cells. (E) Immunoblot for DR3 in 10K pellet fraction of HUVEC after tran
transfected with empty vector; Lane 3, HUVEC transfected with DR3-flag. Two
antibody (upper blot) and anti-Flag (lower blot). PNS: post nuclear supernatan
100KP: 100k pellet. 50 μg proteins from each fraction was analyzed by immunKidney tissues were treated with media alone, TL1A, or
TNF for 3 hours, and then processed and immunostained
for the active form of NF-κB (NF-κBp65). No NF-κB
activation was detected in untreated normal kidney
cultures either in glomerular EC or interstitial EC. Some
peritubular capillary EC were positive for DR3 as previously
reported (Figure 1A-C). In TL1A-treated cultures, the
interstitial EC positive for DR3 showed strong signal for
NF-κBp65 indicative of NF-κB activation (Figure 1D-F).
NF-κB activation was not observed in glomerular EC
(Figure 1D insert). TNF treatment induced more wide-
spread NF-κB activation in interstitial vascular EC and in
glomeruli EC (Figure 1G-I), findings which are consistent
with our previous report that TNF receptors are widely
distributed in kidney tissue.
Expression of DR3 in cultured EC
To investigate mRNA expression for DR3, we extracted
total RNA from TF-1 cells (as positive control) and
HUVEC. A primer was selected to amplify the full length
DR3 open reading frame that extends from exon 2 to exon
10, allowing the possibility of amplifying various splicingVEC expressed full-length DR3 mRNA, which was the same as that of
positive cell surface staining on TF-1 cells and a very low level of
showed both cell types express a full-length 59kDa DR3 in the 10KP
as stronger than that of HUVEC with equal protein loading. Both cells
ed concentration dependent IκBα degradation in TF-1 cells. While TNF
κBp65 was only detected after TNF treatement in the nuclear fraction
sfection. Lane 1, TF1 10K pellet as positive control; Lane 2, HUVEC
gels with same sample loading were immunoblotted with anti-DR3
t. 10KS: 10k supernatant. 10KP: 10k pellet. 100KS: 100k supernatant.
oblotting, blots were representatives of at least 3 separate experiments.
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product was amplified from HUVEC that was the same
size as that of TF-1 cells (Figure 2A), and the sequences of
both products were identical (data not shown), indicating
that HUVEC express mRNA encoding full length DR3.
We then investigated whether HUVEC express DR3 on
their surface. Monoclonal anti-DR3 antibody was used
to detect cell surface DR3 by flow cytometry. TF-1
cells showed positive fluorescent staining for DR3
(1.61 ± 0.16 units), while there was only weak fluorescent
staining for DR3 on HUVEC (0.15 ± 0.01 units) (Figure 2B).
To further characterise DR3 protein expression we per-
formed subcellular fractionation and immunoblotting with
an anti-DR3 C-terminus antibody. The predicted full length
59 kDa protein was detected in the membrane fraction of
both HUVEC and TF-1 cells, with TF-1 expressing more
DR3 than HUVEC (Figure 2C), consistent with the results
from flow cytometry.
Consistent with previous reports we found that TL1A
degraded IκBα in TF1 cells (Figure 2D). However, we did
not find evidence of activation of the classical NF-κB
pathway in cultured cells. Specifically, treatment with
TNF but not TL1A led to p65 phosphorylation in the
nuclear fraction of TF1 cells (Figure 2D).Figure 3 TL1A induced IκBα degradation in HUVEC. (A) HUVEC transfec
concentration of TL1A for 30 minutes, IκBα showed a clear degradation after TL
of 3 separate experiments. (B) Densitometry analysis showed a significant increa
EC compared to the mock transfected (13.3 ± 4 vs.4.3 ± 3.2, 29 ± 5.5 vs.7.2 ± 5.6
compared to TL1A 0 μg/ml IκBα densities. Results were mean ± SE from 3 expe
treatment between HUVEC transfected with empty vector and DR3.We have found that the magnitude of IκBα degradation
following TNF stimulation is related to the number of cell
surface TNF receptors [12,13]. We tried to up-regulate
EC’s surface DR3 using cytokines, including TNF-α and
IFN-γ alone and in combination without success. Then
we transiently transfected HUVEC to increase expression
of DR3, using a DR3-Flag construct, followed by flow
cytometry and immunoblotting to confirm up-regulation
of DR3. Although the major band expressed after transfec-
tion was a shorter form of DR3 (as recognized by both
anti-DR3 antibody and anti-Flag anti-body), the full length
form of DR3 did increase significantly after transfection
(Figure 2E).
Function of DR3 in EC
DR3 and mock-transfected HUVEC were then stimulated
with three different concentrations of TL1A, 0.02, 0.2 and
2μg/ml. Mock-transfected HUVEC treated with 2 μg/ml
of TL1A showed some degree of IκB-degradation not
statistically significant compared to the untreated
cells. In comparison, DR3-transfected HUVEC showed a
concentration dependent IκBα degradation (Figure 3A),
which was more pronounced after treatment with 0.2
and 2μg/ml TL1A compared to mock-transfected cellsted with mock vector or DR3 were treated with ascending
1A stimulation for the DR3-Flag transfected EC. Blots were representatives
se in IκBα degradation by TL1A at 0.2 and 2 μg/ml for the DR3 transfected
respectively) (p < 0.05). Values were expressed as percentages of reduction
riments. (C, D) There was no difference in IκBα degradation after TNF
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difference in IκBα degradation between mock and
DR3-transfected cells after treated with various concentra-
tion of TNF (Figure 3C, D).
E-selectin expression in HUVEC is NF-κB dependent;
we therefore investigated whether the TL1A induced
IκBα degradation led to up-regulation of E-selectin.
HUVEC transfected with empty vector did not show
cell surface E-selectin change after TL1A treatment
(Figure 4A). In comparison, transfection with DR3 resulted
in a significant increase in expression of cell surface
E-selectin after TL1A treatment for 2 or 4 hours com-
pared to the mock transfected. There was up-regulation
of E-selectin expression even without TL1A treatment
albeit small which might be due to the presence of in-
creased DR3 level and endogenous TL1A in HUVEC. The
increased level of E-selectin in DR3-transfected TL1A-Figure 4 TL1A induced E-selectin expression in HUVEC. HUVEC transfe
2 and 4 hours. Cell surface E-selectin was measured by flow cytometry. (A)
transfected with mock vector after TL1A treatment. In contrast, a significan
with DR3 compared with empty vector at each of the two time points me
significant increase in E-selectin expression at 4 hours after TL1A treatment
Results were mean of units ± SE from 3 experiments. (B) There was no diffe
vector and DR3 vector after TNF treatment.treated HUVEC appeared to be time-dependent, sig-
nificant at a 4 hour time point (Figure 4A). The TL1A ef-
fect was slower and less pronounced than that of TNF
(Figure 4B), and DR3 transfection had no effect on
cell surface E-selectin up-regulation by TNF.
To determine whether EC from other vascular beds
constitutively signal through DR3, we studied DR3
response to treatment with TL1A in HDMEC and
HPAEC. HDMEC and HPAEC degraded IκBα in response
to treatment with TNF, but not TL1A. Consistent with this
we could not detect full length DR3 by immunoblotting in
HDMEC and HPAEC (see Additional file 1).
Responses of EC to TL1A in DR3 knockout mouse
We next examined the effects of TL1A on DR3 knock-
out (KO) mice to verify the specificity of in vitro
data. Untreated cultures of DR3 wild type (WT) andcted with mock vector or DR3 were treated with 0.2 μg/ml of TL1A for
There was no significant change in E-selectin expression for HUVEC
t increase in E-selectin expression was detected in HUVEC transfected
asured (1.5 ± 0.2vs.2.7 ± 0.5 and1.7 ± 0.7vs.3.1 ± 0.6) (p < 0.05). There was
for the HUVEC transfected with DR3 but not at 2 hour time point.
rence in E-selectin expression between HUVEC transfected with empty
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(Figure 5A-C and J-L). DR3wt but not DR3ko cul-
tures treated with TL1A showed NF-κB activation in EC
(Figure 5D-F and M-O), while TNF treatment induced a
similar degree of NF-κB activation in EC in both DR3wt
and DR3ko cultures (Figure 5G-I and P-R). To determine
whether TL1A can activate EC in other vascular beds weFigure 5 TL1a induced NF-κB activation in renal interstitial vascular e
wild type (wt) and DR3 knockout (ko) mice were treated with TL1A or TNF
Untreated (UT) DR3wt showed no positive staining for NF-κB activation in
interstitial EC were positive for NF-κB activation after TL1A treatment. (G-I) mo
(J-L) untreated DR3ko showed no staining for NF-κB activation in vascular EC
vascular EC. (P-R) TNF-treated DR3ko showed positive staining for NF-κB activ
were representative of 3 experiments.examined the effects of TL1A on mouse heart tissue. There
were occasional EC positive for NF-κB/p65 in untreated
tissue of DR3wt and DR3ko mice (Figure 6a A, D), TL1A
treatment induced NF-κB activation in EC in DR3wt mice
but not DR3ko mice (Figure 6a B, E and Figure 6b), while
TNF induced a similar degree of NF-κB activation in EC in
DR3wt and DR3ko mice (Figure 6a C, F and Figure 6b).ndothelial cells in mouse organ cultures. Kidney tissue from DR3
and immunolabeled as described in materials and methods. (A-C)
CD31 positive EC from glomerulus or interstitial vessels. (D-F) some
re vascular EC were positive for NF-κB activation after TNF treatment.
. (M-O) TL1A-treated DR3ko showed no staining for NF-κB activation in
ation in vascular EC. Arrow for BvEC: blood vessel endothelial cells. Results
Figure 6 TL1A induced NF-κB activation in vascular endothelial cells in mouse heart organ cultures. (6a) Heart tissue from DR3 wild type
(wt) and DR3 knock-out (ko) mice were treated with TL1A or TNF and immunolabeled as described in materials and methods. DR3wt showed
more nuclear NF-κB activation in CD31 positive EC after TL1A treatment (B) compared to the untreated (A). There was similar odd nuclear NF-κB
activation in DR3ko mice EC between TL1A treated (E) and untreated cultures (D). TNF induced a more profound nuclear NF-κB activation in EC
of both DR3wt and DR3ko (C and F). Results were representative of 3 experiments. (6b) Graph showed a statistical difference in number of EC in
TL1A treated tissue with NF-κB activation in DR3wt compared to DR3ko (p < 0.05) (*).
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In this study we have shown for the first time that human
EC express full length DR3, which supports a more
widespread cellular expression of DR3 than its original
description as a lymphoid cell receptor [14-16]. Moreover,
EC have all the machinery necessary to respond upon
DR3 up-regulation. Exogenous TL1A can induce NF-κB
activation in EC both in vitro and in vivo.
TNF superfamily members play an important role in
renal injury [17], and the differential expression of TNF
receptor (TNFR) superfamily members may have
functional implications [18]. TNFRs are widely expressed
in glomerular and interstitial EC, while DR3 is detected
only in some interstitial EC. Our results show that, like
TF-1 cells, HUVEC express both DR3 transcript and pro-
tein. Although we were unable to identify a pathophysio-
logical stimulus that would up-regulate full length
DR3 in EC, we were able to increase surface expression of
DR3 by transfection, which resulted in IκBα degradation by
TL1A treatment. This potential function of DR3 in EC issupported by our in situ study of EC in TL1A-treated kidney
tissue.
Pre-ligand-binding assembly of TNFR into trimer com-
plexes is critical in TNF mediated signaling [19], which is
based on a ligand-receptor trimerisation. It is possible that
TL1A signaling does not occur in untreated HUVEC
because there is both insufficient level of DR3 on the
surface, and other forms of non-signaling DR3 interfere
with TL1A binding. The lack of response to TL1A cannot
be attributed to inability of DR3 to signal IκBα degradation
in HUVEC, as expressing full length DR3 by transfection
allowed TL1A to degrade IκBα. The lower molecular
weight band detected by immunoblotting with anti-flag
and anti-DR3 after transfection may be an isoform of DR3
that is able to bind TL1A and interfere with its signalling,
as reported for other death receptors like DR4 and
DR5 [20]. This DR3 isoform differs from the reported
soluble form of DR3 [9] as it is detected only in the
membrane fraction and not the soluble fraction. It is
unlikely to be the signaling isoform inducing IκBα
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in TF-1 cells. Moreover, the relatively abundant ex-
pression of this shorter isoform after transfection did
not make HUVEC more responsive to TL1A than TF-1
cell, which in turn indicate that it is full-length DR3
that TL1A signals through. Further studies on iso-
forms of DR3 are needed to support our hypothesis.
Our results are consistent with Migone et al., when
they over expressed TL1A and DR3 in 293T cells,
NF-κB activation could be detected, whereas VEGI
failed to do so [10].
NF-κB factors belong to the Rel family of transcription
factor; they mediated biological activity through classical
and alternative pathways. Our results in tissue support
DR3 signaling through the classical pathway similar to
TNFR1, which induces IκBα degradation and RelA/p65
activation [17]. Although we were unable to demonstrate
activation of RelA/p65 in TF1 cells following IκBα
degradation, we have shown that TL1A induces RelA/p65
activation in EC in situ. Furthermore, we demonstrated
TL1A induced E-selectin expression in DR3 transfected
HUVEC, indicating functional activation of NF-κB in
these cells. We have previously observed differences in
death receptor signaling in situ compared to in vitro [18].
Whether the alternative pathway is involved requires
further studies. Although TL1A-DR3 interaction has
been extensively studied in autoimmune diseases such
as inflammatory bowel diseases, experimental allergic
encephalomyelitis and rheumatoid arthritis [21-23], its
physiological role in immune reaction is still unclear.
Furthermore it has been shown to have functions out-
side of the immune system, including atherosclerosis
and aging [24,25]. Both TL1A and DR3 expression
levels are low under physiological conditions, but can
be acutely up-regulated in inflammatory reaction. As EC
also express TL1A, the dynamic balance of the ligand
and receptor in endothelial systems could be critical
for maintaining normal function of these cells. Over
expression of either ligand or receptor could lead to
inflammation or apoptosis [26]. In normal kidney
where most cells are negative for DR3, TL1A may be
unable to induce signaling. However, in human allograft
rejection infiltrating mononuclear cells, which express
high levels of DR3, are able to respond to TL1A, the
DR3-TL1A interaction may form a positive feedback
loop inducing an inflammatory reaction.Conclusion
EC express full length and functional DR3. The TL1A
and DR3 system may play an important role in vascular
injury in allograft rejection and atherosclerosis where
significant increases in both TL1A and DR3 have been
reported.Additional file
Additional file 1: Expression and signaling of DR3 in human
microvascular and pulmonary artery endothelial cells. (A) Whole cell
lysates from HMVEC and HPAEC were immunoblotted for DR3 expression.
TF-1 was positive for full length DR3, while both endothelial cells were
negative. (B) HMVEC and HPVEC were treated with ascending concentration
of TL1A, there was no IκBα degradation detected.
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